Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Preclinical efficacy and safety of KCNH2-G628S gene therapy for postoperative atrial fibrillation.

Liu Z, Hutt JA, Rajeshkumar B, Azuma Y, Duan KL, Donahue JK.

J Thorac Cardiovasc Surg. 2017 Nov;154(5):1644-1651.e8. doi: 10.1016/j.jtcvs.2017.05.052. Epub 2017 May 23.

2.

Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance.

Rajeshkumar B, Agrawal P, Rashighi M, Saidi RF.

Int J Organ Transplant Med. 2015;6(2):55-60.

3.

Treatment of peritoneal carcinomatosis with intraperitoneal administration of Ad-hARF.

Rajeshkumar BR, Paliwal S, Lambert L, Grossman SR, Whalen GF.

J Surg Res. 2015 Jul;197(1):85-90. doi: 10.1016/j.jss.2015.03.048. Epub 2015 Mar 26.

PMID:
25935465
4.

Human adipose-derived mesenchymal stem cells attenuate liver ischemia-reperfusion injury and promote liver regeneration.

Saidi RF, Rajeshkumar B, Shariftabrizi A, Bogdanov AA, Zheng S, Dresser K, Walter O.

Surgery. 2014 Nov;156(5):1225-31. doi: 10.1016/j.surg.2014.05.008. Epub 2014 Sep 26.

PMID:
25262218
5.

Higher flow rates improve heating during hyperthermic intraperitoneal chemoperfusion.

Furman MJ, Picotte RJ, Wante MJ, Rajeshkumar BR, Whalen GF, Lambert LA.

J Surg Oncol. 2014 Dec;110(8):970-5. doi: 10.1002/jso.23776. Epub 2014 Aug 29.

PMID:
25171494
6.

Human C1 inhibitor attenuates liver ischemia-reperfusion injury and promotes liver regeneration.

Saidi RF, Rajeshkumar B, Shariftabrizi A, Dresser K, Walter O.

J Surg Res. 2014 Apr;187(2):660-6. doi: 10.1016/j.jss.2013.09.009. Epub 2013 Oct 2.

PMID:
24433870
7.

Carnoy's in Aggressive Lesions: Our Experience.

Rajeshkumar BP, Rai KK, Geetha NT, Shivakumar HR, Upasi AP.

J Maxillofac Oral Surg. 2013 Mar;12(1):42-7. doi: 10.1007/s12663-012-0371-9. Epub 2012 Apr 4.

8.

Therapeutic targeting of C-terminal binding protein in human cancer.

Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D, Whalen GF, Lyle S, Schiffer CA, Grossman SR.

Cell Cycle. 2010 Sep 15;9(18):3740-50. doi: 10.4161/cc.9.18.12936. Epub 2010 Sep 8.

9.

Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.

Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW; Cancer and Leukemia Group B.

Clin Cancer Res. 2005 Nov 15;11(22):8109-13.

10.

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663.

J Clin Oncol. 2003 Jul 15;21(14):2673-8.

PMID:
12860943
11.

A review of odontogenic keratocyst with a report of unusual occurrence in the maxilla.

Nayak UA, Rajeshkumar BP, Ahmed J, Baliga MJ.

Indian J Dent Res. 2002 Jul-Dec;13(3-4):183-6. Review.

PMID:
12765099
12.

Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.

Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE.

Semin Oncol. 2001 Aug;28(4 Suppl 15):32-9.

PMID:
11685726
13.

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.

Cancer Res. 1999 Jun 1;59(11):2511-5.

Supplemental Content

Loading ...
Support Center